Patents by Inventor Nikhil Pargaonkar

Nikhil Pargaonkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for manufacturing capsules with ingestible event markers
    Patent number: 11793419
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: October 24, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Jeremy Frank, Nikhil Pargaonkar, Raymond Schmidt, Robert Azevedo, Kurt Scheinpflug, Nikolaus Leist, Chris Dong, Hiren Patel, Peter Bjeletich, Robert Duck
  • Lisinopril compositions with an ingestible event marker
    Patent number: 11684605
    Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: June 27, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kurt Scheinpflug, Nikhil Pargaonkar, Chris Dong, Ai Ling Ching, Dawn Adkin
  • METHODS FOR MANUFACTURING CAPSULES WITH INGESTIBLE EVENT MARKERS
    Publication number: 20230076111
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 9, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Jeremy FRANK, Nikhil PARGAONKAR, Raymond SCHMIDT, Robert AZEVEDO, Kurt SCHEINPFLUG, Nikolaus LEIST, Chris DONG, Hiren PATEL, Peter BJELETICH, Robert DUCK
  • Methods for manufacturing capsules with ingestible event markers
    Patent number: 11529071
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 20, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Jeremy Frank, Nikhil Pargaonkar, Raymond Schmidt, Robert Azevedo, Kurt Scheinpflug, Nikolaus Leist, Chris Dong, Hiren Patel, Peter Bjeletich, Robert Duck
  • LISINOPRIL COMPOSITIONS WITH AN INGESTIBLE EVENT MARKER
    Publication number: 20220079919
    Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.
    Type: Application
    Filed: October 6, 2021
    Publication date: March 17, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kurt Scheinpflug, Nikhil Pargaonkar, Chris Dong, Ai Ling Ching, Dawn Adkin
  • Lisinopril compositions with an ingestible event marker
    Patent number: 11166939
    Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 9, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO. LTD
    Inventors: Kurt Scheinpflug, Nikhil Pargaonkar, Chris Dong, Ai Ling Ching, Dawn Adkin
  • METHODS FOR MANUFACTURING CAPSULES WITH INGESTIBLE EVENT MARKERS
    Publication number: 20210212592
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Application
    Filed: September 28, 2020
    Publication date: July 15, 2021
    Applicant: Otsuka America Pharmaceutical, Inc.
    Inventors: Jeremy FRANK, Nikhil PARGAONKAR, Raymond SCHMIDT, Robert AZEVEDO, Kurt SCHEINPFLUG, Nikolaus LEIST, Chris DONG, Hiren PATEL, Peter BJELETICH, Robert DUCK
  • Methods for manufacturing capsules with ingestible event markers
    Patent number: 10820831
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 3, 2020
    Inventors: Jeremy Frank, Nikhil Pargaonkar, Raymond Schmidt, Robert Azevedo, Kurt Scheinpflug, Nikolaus Leist, Chris Dong, Hiren Patel, Peter Bjeletich, Robert Duck
  • LISINOPRIL COMPOSITIONS WITH AN INGESTIBLE EVENT MARKER
    Publication number: 20190216776
    Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.
    Type: Application
    Filed: April 25, 2018
    Publication date: July 18, 2019
    Inventors: Kurt Scheinpflug, Nikhil Pargaonkar, Chris Dong, Ai Ling Ching, Dawn Adkin
  • COMPOSITIONS OF PHARMACEUTICAL PRODUCT WITH INGESTIBLE EVENT MARKER
    Publication number: 20190167595
    Abstract: In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the group consisting of copper iodide, copper chloride, copper bromide, copper sulfate, copper formate, or combinations thereof.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Mark ZDEBLICK, Markus CHRISTEN, Nikhil PARGAONKAR, Nikolaus LEIST, Kurt SCHEINPFLUG, Patricia JOHNSON, Benedict COSTELLO
  • Sustained release oral dosage forms of an R-baclofen prodrug
    Patent number: 10071068
    Abstract: Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: September 11, 2018
    Assignee: XENOPORT, INC.
    Inventors: David E. Edgren, David J. Kidney, Nikhil Pargaonkar, Derrick K. Kim, Gorm Yoder, Sarni Karaborni
  • METHODS FOR MANUFACTURING CAPSULES WITH INGESTIBLE EVENT MARKERS
    Publication number: 20180110441
    Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 26, 2018
    Inventors: Jeremy Frank, Nikhil Pargaonkar, Raymond Schmidt, Robert Azevedo, Kurt Scheinpflug, Nikolaus Leist, Chris Dong, Hiren Patel, Peter Bjeletich
  • Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
    Patent number: 8435562
    Abstract: Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms are disclosed.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: May 7, 2013
    Assignee: XenoPort, Inc.
    Inventors: Chen Mao, Nikhil Pargaonkar, Laura E. Maurer, Sarina Grace Harris Ma
  • ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG
    Publication number: 20110184060
    Abstract: Oral dosage forms with a high loading of 4-({[(2-methylpropanoyloxy)ethoxy]carbonylamino}methyl)cyclohexanecarboxylic acid are disclosed.
    Type: Application
    Filed: January 20, 2011
    Publication date: July 28, 2011
    Inventors: Sarina Grace HARRIS MA, Nikhil Pargaonkar, Sami Karaborni
  • PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF A LEVODOPA PRODRUG AND METHODS OF USE
    Publication number: 20110111024
    Abstract: Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms are disclosed.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 12, 2011
    Inventors: Chen MAO, Nikhil Pargaonkar, Laura E. Mauer, Sarina Grace Harris Ma
  • SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG
    Publication number: 20100255093
    Abstract: Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.
    Type: Application
    Filed: March 3, 2010
    Publication date: October 7, 2010
    Applicant: XenoPort, Inc.
    Inventors: David E. Edgren, David J. Kidney, Nikhil Pargaonkar, Derrick K. Kim, Gorm Yoder, Sami Karaborni
  • POLYMER-ENCAPSULATED MICROSPHERES
    Publication number: 20080069778
    Abstract: A polymer-encapsulated phospholipid microsphere, comprising a plurality of lipid molecules disposed in a liquid and arranged to define an enclosed space, and one or more polymers partially or completely encapsulating that enclosed space. The one or more polymers may be functionalized with either a therapeutic agent and/or a targeting ligand either before, or after, deposition of the polymer onto the phospholipid microsphere.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 20, 2008
    Applicant: IMARX THERAPEUTICS, INC.
    Inventor: Nikhil Pargaonkar